ACELINK THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- AceLink Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06114329
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat sen University, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Xiangya Hospital of Central South University, Changsha, Hunan, China
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Autosomal Dominant Polycystic Kidney
- Interventions
- Drug: AL01211 or Placebo (Part A)Drug: AL01211 or Placebo (Part B)
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- AceLink Therapeutics, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT04908462
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
News
No news found